Clinical Trials by Condition
Please find clinical trials at HSS listed by the following conditions:
Lupus
| IRB# |
Clinical Trial |
Principal Investigator |
| 22122 |
PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE) |
Jane E. Salmon, MD |
| 23081 |
MINDFULL: A Randomized, Controlled Pilot Study of a Cognitive Rehabilitation Intervention Program in Systemic Lupus Erythematosus Patients |
Melanie J. Harrison, MD, MS |
| 25058 |
EXPLORER: A randomized, double-blind, placebo controlled, multicenter, phase II/III study to evaluate the efficacy and safety of rituximab in subjects with moderate to severe systemic lupus erythematosus |
Michael D. Lockshin, MD |
| 25085 |
Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients |
Melanie J. Harrison, MD, MS |
| 26006 |
LUNAR: A phase III, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of rituximab in subjects with class III or IV lupus nephritis |
Michael D. Lockshin, MD |
| 26044 |
A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study To Evaluate Safety And Tolerability Of A Single IV Dose Of MEDI-545, A Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes |
Kyriakos Kirou, MD |
| 27058 |
A Phase I, Randomized, Double-blind, Placebo-controlled, Escalating Single- and Multiple-dose Study of the Safety, Tolerability, and Pharmakokinetics of RhuMab IFN alpha in Adults with Systemic Lupus Erythematosus |
Kyriakos A. Kirou, MD |
| 27076 |
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 Week Study to Evaluate the Efficacy and Safety of Belimumab (GHS1006, LymphoStat-B), A fully Human monoclonal Anti-BlyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE). |
Michael D. Lockshin, M.D. |
| 27089 |
A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus(SLE) |
Kyriakos A. Kirou, MD, FACR |
| 27135 |
The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study |
Kyriakos A. Kirou, MD |
| 28027 |
A Phase 1b Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation study with an open-label extension to evaluate the safety and tolerability of multiple IV doses of Medi-545, a fully Human Anti-interferon-alpha Monoclonal Antibody, in patients with Systemic Lupus Erythematosus |
Kyriakos A. Kirou, MD |
| 93029 |
Fc Receptor Function in Normals and Systemic Lupus Erythematosus (SLE) |
Jane E. Salmon, MD |
| 95004 |
Autoimmune Disease Registry and Repository |
Jane E. Salmon, MD |
Please visit the Mary Kirkland Center for Lupus Research and the Lupus Clinical Trials Consortium for more information on lupus research.
Antiphospholipid Syndrome
Arthritis
| IRB# |
Clinical Trial |
Principal Investigator |
| 26043 |
A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial |
Lisa A. Mandl, MD, MPH |
| 23034 |
Open Label Trial for Treating Carpometacarpal Osteoarthritis: PILOT STUDY - Sub-study on Normal Controls |
Lisa A. Mandl, MD, MPH |
| 24067 |
Database of the Gosden Robinson Early Arthritis Center (EAC): Analysis of Types of Patients Recruited to an Urban EAC |
Lisa C. Vasanth, MD |
| 23108 |
Evaluation of Intra-articular Injuries as Predictors of Function and Arthritis |
Robert G. Marx, MD |
| 27001 |
Incidence and Severity of Nausea after Primary Total Hip Arthroplasty for Osteoarthritis |
Jacques T. YaDeau, MD, PhD |
| 23017 |
CORRONA Data Collection Program |
Melanie J. Harrison, MD, MS |
| 25107 |
Prospective Assessment of the Effects of Hyalgan on Cartilage in Patients with Primary Osteoarthritis |
Lisa Mandl, MD, MPH |
|
A Double-Blind, Randomized Trial of Intra-Articular injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three-injection regimen Efficacy and Duration-20 mg/2ml Dose: Tread-20): Sanofi Protocol #L-9385 |
|
| 25022 |
Quantitative Assessment of the Synovial Vascularity in Early Inflammatory Arthritis |
Lisa A. Mandl, MD, MPH |
Arthroplasty
| IRB# |
Clinical Trial |
Principal Investigator |
| 28041 |
The Effect of Ischemic Preconditioning on Systemic Inflammatory Markers after Total Knee Arthroplasty |
Stavros G. Memtsoudis, MD |
| 21137 |
Minimally Invasive Surgical Approach versus Standard Total Knee Arthroplasty: A Prospective Randomized Double Blinded Study Comparing Postoperative Strength |
Bryan J. Nestor. MD |
| 26079 |
Deep Vein Thrombosis (DVT) Prevention in Total Hip Replacement: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH) |
Douglas E. Padgett, MD |
| 26132 |
Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: The HSS Knee Arthroplasty Cohort |
Thomas P. Sculco, MD |
| 27027 |
Vitamin D Status Among Trauma Patients; Acute Fractures/Non-unions vs. Primary Joint Arthroplasty (control population) |
Joseph M. Lane, MD |
| 27001 |
Incidence and Severity of Nausea after Primary Total Hip Arthroplasty for Osteoarthritis |
Jacques T. YaDeau, MD, PhD |
| 26073 |
Evaluation of migration of a cementless, flat, tapered femoral component using RSA |
Edwin P. Su, MD |
| 21072 |
The Genetic Factor: Identifying Patients at High Risk for Developing Pulmonary Embolism (PE) After Orthopedic Surgery (Upper Extremity, Spine, THR, TKR) Using A Molecular Screening Test |
Geoffrey H. Westrich, MD |
| 22007 |
Hyalgan Treatment of Osteoarthritis in Post-Operative Knee Arthroplasty Patients |
Geoffrey Westrich, MD |
Foot and Ankle Conditions
Knee Conditions
Shoulder Conditions
Spine Conditions
Skeletal Dysplasias
Scleroderma
Osteoporosis